Product Name :
CNQX disodium
Description:
CNQX (FG9065) is a potent and competitive AMPA/kainate receptor antagonist with IC50s of 0.3 μM and 1.5 μM, respectively. CNQX is a competitive non-NMDA receptor antagonist. CNQX blocks the expression of fear-potentiated startle in rats.
CAS:
479347-85-8
Molecular Weight:
276.12
Formula:
C9H2N4Na2O4
Chemical Name:
sodium 6-cyano-7-nitroquinoxaline-2,3-bis(olate)
Smiles :
[Na+].[Na+].N#CC1=CC2=NC([O-])=C([O-])N=C2C=C1[N+]([O-])=O
InChiKey:
YCXDDPGRZKUGDG-UHFFFAOYSA-L
InChi :
InChI=1S/C9H4N4O4.2Na/c10-3-4-1-5-6(2-7(4)13(16)17)12-9(15)8(14)11-5;;/h1-2H,(H,11,14)(H,12,15);;/q;2*+1/p-2
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
CNQX (FG9065) is a potent and competitive AMPA/kainate receptor antagonist with IC50s of 0.3 μM and 1.5 μM, respectively. CNQX is a competitive non-NMDA receptor antagonist. CNQX blocks the expression of fear-potentiated startle in rats.|Product information|CAS Number: 479347-85-8|Molecular Weight: 276.12|Formula: C9H2N4Na2O4|Synonym:|CNQX 2Na|CNQX Disodium|FG9065 disodium|Related CAS Number:|115066-14-3 (free acid)|Chemical Name: sodium 6-cyano-7-nitroquinoxaline-2,3-bis(olate)|Smiles: [Na+].[Na+].N#CC1=CC2=NC([O-])=C([O-])N=C2C=C1[N+]([O-])=O|InChiKey: YCXDDPGRZKUGDG-UHFFFAOYSA-L|InChi: InChI=1S/C9H4N4O4.2Na/c10-3-4-1-5-6(2-7(4)13(16)17)12-9(15)8(14)11-5;;/h1-2H,(H,11,14)(H,12,15);;/q;2*+1/p-2|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: Soluble in DMSO|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.{{Teprotumumab} MedChemExpress|{Teprotumumab} IGF-1R|{Teprotumumab} Technical Information|{Teprotumumab} In Vitro|{Teprotumumab} supplier|{Teprotumumab} Epigenetics} |Drug Formulation: To be determined.{{Ulixertinib} medchemexpress|{Ulixertinib} ERK|{Ulixertinib} Biological Activity|{Ulixertinib} Formula|{Ulixertinib} custom synthesis|{Ulixertinib} Autophagy} |HS Tariff Code: 382200|How to use|In Vitro:|CNQX (FG9065; 2-5 μM) reversibly blocks the Schaffer collateral and mossy fibre excitatory postsynaptic potential (EPSP), while sparing the fast and slow GABA-mediated inhibition in superfusion of hippocampal slices.PMID:24580853 CNQX (1-5 μM) produces a selective and dose-dependent reduction in the amplitude of the monosynaptic component of the DR-VRR recorded from lumbar spinal segments.|In Vivo:|CNQX (FG9065 disodium; 0.75-3 mg/kg; IP; 20 min before testing) decreased the number of cocaine responses in a dose-dependent manner during the first 15-min cocaine-free interval. The bilateral infusion of CNQX (0.5 or 1.25 μg) into the amygdala or dorsal hippocampus 10 min prior to a retention test partially blocks the expression of stepdown inhibitory avoidance in rats 24 h after training. CNQX causes a complete blockade at a dose of 0.5 μg.|References:|Sergeeva OA, De Luca R, Mazur K, Chepkova AN, Haas HL, Bauer A. N-oleoyldopamine modulates activity of midbrain dopaminergic neurons through multiple mechanisms. Neuropharmacology. 2017 Jun;119:111-122. doi: 10.1016/j.neuropharm.2017.04.011. Epub 2017 Apr 9. PubMed PMID: 28400256.Zagrean AM, Spataru A, CeangaM, Zagrean L. The single versus combinatorial effects of MK-801, CNQX, Nifedipine and AP-3 on primary cultures of cerebellar granule cells in an oxygen-glucose deprivation model. Rom J Morphol Embryol. 2014;55(3):811-6. PubMed PMID: 25329107.Gigout S, Louvel J, Rinaldi D, Martin B, Pumain R. Thalamocortical relationships and network synchronization in a new genetic model “in mirror” for absence epilepsy. Brain Res. 2013 Aug 7;1525:39-52. doi: 10.1016/j.brainres.2013.05.044. Epub 2013 Jun 3. PubMed PMID: 23743261.Products are for research use only. Not for human use.|
